Lytix Biopharma ASA: Mandatory notification of trade by primary insider
Lytix Biopharma ASA (LYTIX) · publisert 2. september 2026 kl. 22:01 · vis på NewsWeb
Transaksjoner
| Person | Rolle | Type | Volum | Pris | Dato | ISIN | Handelsplass |
|---|---|---|---|---|---|---|---|
| Eric Falcand | Styreleder | Kjøp | 12 000 | 8,3019 NOK | 3 dager siden | NO0010405780 | Euronext Growth Oslo |
Vedlegg
- Lytix Biopharma ASA - PDMR Appendix.pdf (application/pdf, originaldokument)
Meldingstekst
Oslo, 2 September 2026 – Eric Falcand, Chair of the Board of Directors and primary insider in Lytix Biopharma ASA, has today purchased 12,000 shares in Lytix Biopharma ASA at an average price of NOK 8.3019 per share.
Following the transaction, Eric Falcand holds 12,000 shares in Lytix Biopharma ASA.
Please refer to the attached notification form for further details.
For further information, please contact:
Gjest Breistein
Chief Financial Officer
E-mail: Gjest.Breistein@lytixbiopharma.com
This information is subject to disclosure under section 5-12 of the Norwegian Securities Trading Act and Article 19 of the Market Abuse Regulation.